Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis

International Journal of Oncology

Volumn 27, Issue 3, 2005, Pages 713-720

  Schlomm, Thorsten ^a   Luebke, Andreas M ^a   Sültmann, Holger ^b   Hellwinkel, Olaf J C ^a   Sauer, Ulrich ^c   Poustka, Annemarie ^b   David, Kerstin A ^d   Chun, Felix K H ^a   Haese, Alexander ^a   Graefen, Markus ^a   Erbersdobler, Andreas ^a   Huland, Hartwig ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c PALM Microlaser Technologies AG   (Germany)

^d ISRAELITISCHES KRANKENHAUS   (Germany)

Author keywords

Gene expression; Laser microdissection; Prostate cancer; Tissue banking

Indexed keywords

RNA;

ARTICLE; CANCER STAGING; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; UP-REGULATION;

EID: 24344450324     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Miller DC, Hafez KS, Stewart A, Montie JE and Wei JT: Prostate carcinoma presentation, diagnosis, and staging: an update from the National Cancer Data Base. Cancer 98: 1169-1178, 2003.
2. Epstein JI, Walsh PC and Carter HB: Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage Tic disease. J Urol 166: 1688-1691,2001.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999.
4. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE and Loveland KG: Prediction of post-radical prostatectomy pathological outcome for stage Tic prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162: 1346-1351, 1999.
5. Dash A, Maine IP, Varambally S, Shen R, Chinnaiyan AM and Rubin MA: Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. Am J Pathol 161: 1743-1748,2002.
6. Huang J, Qi R, Quackenbush J, Dauway E, Lazaridis E and Yeatman T: Effects of ischemia on gene expression. J Surg Res 99:222-227,2001.
7. Thelen P, Burfeind P, Grzmil M, Voigt S, Ringert RH and Hemmerlein B: cDNA microarray analysis with amplified RNA after isolation of intact cellular RNA from neoplastic and nonneoplastic prostate tissue separated by laser microdissections. Int J Oncol 24: 1085-1092, 2004.
8. Spruessel A, Steimann G, Jung M, Lee SA, Carr T, Fentz AK, Spangenberg J, Zornig C, Juhl HH and David KA: Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 36: 1030-1037,2004.
9. Ellis M, Davis N, Coop A, Liu M, Schumaker L, Lee RY, Srikanchana R, Russell CG, Singh B, Miller WR, Stearns V, Pennanen M, Tsangaris T, Gallagher A, Liu A, Zwart A, Hayes DF, Lippman ME, Wang Y and Clarke R: Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 8: 1155-1166,2002.
10. Hergenhahn M, Kenzelmann M and Grone HJ: Laser-controlled microdissection of tissues opens a window of new opportunities. Pathol Res Pract 199: 419-423, 2003.
11. Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121, 2001.
12. Burger MJ, Tebay MA, Keith PA, Samaratunga HM, Clements J, Lavin MF and Gardiner RA: Expression analysis of deltacatenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer 100: 228-237, 2002.
13. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826, 2001.
14. Evans AJ: Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 56: 892-897, 2003.
15. Febbo PG and Sellers WR: Use of expression analysis to predict outcome after radical prostatectomy. J Urol 170: S11-S20, 2003.
16. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Strieker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH and Sutherland RL: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63: 4196-4203, 2003.
17. Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Strieker PD, Grygiel JJ, Mack DH and Sutherland RL: Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 22: 6005-6012, 2003.
18. Hessels D, Verhaegh GW, Schalken JA and Witjes JA: Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 4: 513-526, 2004.
19. Jiang Z, Woda BA, Wu CL and Yang XJ: Discovery and clinical application of a novel prostate cancer marker: alphamethylacyl CoA racemase (P504S). Am J Clin Pathol 122: 275-289, 2004.
20. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, De Marzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD and Pollack JR: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad SciUSA 101:811-816,2004.
21. Latil A, Chene L, Cochant-Priollet B, Mangin P, Fournier G, Berthon P and Cussenot O: Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer 103: 306-315,2003.
22. La Tulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V and Gerald WL: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499-4506, 2002.
23. Shen-Ong GL, Feng Y and Troyer DA: Expression profiling identifies a novet alpha-methylacyl-CoA racemase exon with fumarate hydratase homology. Cancer Res 63: 3296-3301, 2003.
24. Weigle B, Fuessel S, Ebner R, Temme A, Schmitz M, Schwind S, Kiessling A, Rieger MA, Meye A, Bachmann M, Wirth MP and Rieber EP: D-GPCR: a novel putative G protein-coupled receptor overexpressed in prostate cancer and prostate. Biochem Biophys Res Commun 322: 239-249, 2004.
25. Wolfgang CD, Essand M, Lee B and Pastan I: T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin. Cancer Res 61: 8122-8126,2001.
26. Wolfgang CD, Essand M, Vincent JJ, Lee B and Pastan I: TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci USA 97: 9437-9442, 2000.
27. Best CJ, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, Bostwick DG, Linehan WM and Emmert-Buck MR: Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol 12: 63-70, 2003.
28. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C and Green JE: Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 62: 5325-5335, 2002.
29. Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA and Stamey TA: Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 169: 1316-1319, 2003.
30. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM and Rubin MA: The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 64: 825-829, 2004.
31. Rhodes DR, Barrette TR, Rubin MA, Ghosh D and Chinnaiyan AM: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433, 2002.
32. Mutter GL, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker HE and Warrington JA: Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics 5: 88, 2004.
33. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M and Grone HJ: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 160: 2169-2180,2002.
34. Meng FJ, Shan A, Jin L and Young CY: The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev 11: 305-309, 2002.
35. Schneider J, Buness A, Huber W, Volz J, Kioschis P, Hafner M, Poustka A and Sultmann H: Systematic analysis of T7 RNA polymerase based in vitro linear RNA amplification for use in microarray experiments. BMC Genomics 5: 29, 2004.
36. Gelmann EP and Semmes OJ: Expression of genes and proteins specific for prostate cancer. J Urol 172: S23-S27, 2004.
37. Scaltriti M, Brausi M, Amorosi A, Caporali A, D'Arca D, Astancolle S, Corti A and Bettuzzi S: Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 108: 23-30, 2004.
38. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL and Gleave ME: Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50: 179-188,2002.
39. Isler SG, Schenk S, Bendik I, Schraml P, Novotna H, Moch H, Sauter G and Ludwig CU: Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol 18: 521-526, 2001.
40. Garrett SH, Sens MA, Shukla D, Flores L, Somji S, Todd JH and Sens DA: Metallothionein isoform 1 and 2 gene expression in the human prostate: downregulation of MT-1X in advanced prostate cancer. Prostate43: 125-135,2000.
41. Gober MD, Smith CC, Ueda K, Toretsky JA and Aurelian L: Forced expression of the H11 heat shock protein can be regulated by DNA methylation and trigger apoptosis in human cells. J Biol Chem 278: 37600-37609, 2003.